Repurposing Clinically Safe Drugs to Modulate DNA Repair Pathway Choice in CRISPR Genome Editing

Study Background and Research Question

Genome editing technologies, particularly CRISPR-Cas9, have transformed biomedical research and therapeutic development by enabling targeted modification of DNA. However, the outcome of CRISPR-induced double-strand breaks (DSBs) depends heavily on the cellular DNA repair pathways engaged: nonhomologous end joining (NHEJ), microhomology-mediated end joining (MMEJ), and homology-directed repair (HDR). Each pathway produces distinct mutational signatures; for example, NHEJ often results in small insertions or deletions, while HDR enables precise sequence replacement. Despite their importance, the choice among these pathways is largely determined by endogenous factors and is difficult to control, limiting the predictability of gene editing outcomes. The reference study (Macak et al., Nature Communications, 2025) addresses the pivotal question: Can existing, clinically safe drugs be repurposed to bias DNA repair pathway choice, thus enhancing the precision, efficiency, and safety of CRISPR-based genome editing?

Key Innovation from the Reference Study

The central innovation of the study lies in its comprehensive drug repurposing screen, encompassing more than 7,000 FDA-approved compounds. Rather than focusing on a few candidate inhibitors or enhancers, the authors systematically profile how diverse small molecules influence the balance between NHEJ, MMEJ, and HDR repair outcomes after CRISPR-induced DSBs in human induced pluripotent stem cells (hiPSCs). This large-scale, unbiased approach not only uncovers new chemical modulators of genome editing precision but also identifies compounds capable of inducing synthetic lethality under specific DNA repair deficiencies. The work sets a new benchmark for integrating pharmacological modulation into the genome editing workflow, moving beyond genetic knockouts and RNA interference to pharmacologically tractable interventions.

Methods and Experimental Design Insights

The screening workflow was thoughtfully designed for high throughput and reproducibility. Human 409B2 iPSCs were engineered to express a doxycycline-inducible Cas9 (iCRISPR) system, enabling controlled induction of DSBs at a specific genomic locus (FRMD7) during drug treatment. The experimental protocol comprised the following key steps:

• Cells were pre-treated with individual drugs or vehicle (DMSO) and then subjected to CRISPR-mediated cleavage.
• After editing, cell survival was measured by a resazurin-based fluorescence assay, providing a quantitative readout of drug cytotoxicity and synthetic lethality.
• Genomic DNA was extracted for high-throughput amplicon sequencing to determine the spectrum and frequency of repair outcomes.
• Sequencing reads were computationally assigned to NHEJ (predominantly 1 bp insertions), MMEJ (≥2 bp deletions with microhomology), or HDR (precise edits using exogenous donor templates).

This approach allowed the authors to simultaneously track editing efficiency, repair fidelity, and cell viability across thousands of drug conditions, revealing not only pathway-specific modulators but also compounds with context-dependent synthetic lethality effects (reference study).

Core Findings and Why They Matter

Several meaningful discoveries emerged from the screen:

• Identification of DNA repair modulators: Distinct drugs were found to either inhibit or enhance specific DSB repair outcomes, shifting the balance between NHEJ, MMEJ, and HDR. For example, known inhibitors such as DNA-PKcs antagonists reduced NHEJ-mediated indels, while others increased HDR frequencies, supporting template-directed editing strategies.
• Roles for ESR2 and AOX1: The study uncovered that drugs targeting estrogen receptor 2 (ESR2) or aldehyde oxidase 1 (AOX1) indirectly modulate key DNA repair proteins (ATM, 53BP1), refining our understanding of repair pathway regulation. Notably, ESR2 silencing combined with NHEJ inhibition led to a marked (mean 4.6-fold) increase in HDR, offering a synergistic strategy for precise editing.
• Synthetic lethality opportunities: Certain compounds induced selective cell death only when a specific DNA repair pathway was genetically or pharmacologically blocked. This principle of synthetic lethality creates opportunities for targeted cancer therapy and for safeguarding against off-target effects in genome editing.

These findings are highly relevant for research in pancreatitis and neurodegenerative disease models, where DNA repair capacity and cell survival are critical determinants of pathogenesis and therapeutic response. The demonstration that repair pathway choice can be pharmacologically redirected provides a scalable platform for improving the precision and safety of gene therapies, as well as for designing more robust disease models (internal review).

Comparison with Existing Internal Articles

The findings of Macak et al. are well-aligned with prior reports on small-molecule modulation of DNA repair, but their systematic screening approach stands out for scale and mechanistic insight. For instance, the article "Dantrolene Sodium Salt: Transforming Calcium Signaling Modulation in Genome Editing" discusses the mechanistic rationale for targeting intracellular calcium signaling to influence repair outcomes. Dantrolene sodium salt, a well-characterized ryanodine receptor antagonist, is highlighted as a tool for modulating calcium-dependent signaling cascades that intersect with DNA repair processes—particularly relevant given the emerging links between calcium homeostasis, DNA damage response, and cell fate decisions.

Further, "Dantrolene, sodium salt: A Benchmark Ryanodine Receptor Antagonist" reviews the compound’s utility in high-reproducibility laboratory workflows, reinforcing the practical value of integrating calcium signaling inhibitors into research on genome stability and synthetic lethality. This complements the reference study’s emphasis on workflow scalability and pharmacological tractability, especially in complex disease models and high-throughput settings.

Limitations and Transferability

Despite its strengths, the study is subject to several limitations:

• Cell type specificity: The findings are based on human iPSC models; extrapolation to primary cells, organoids, or in vivo systems requires further validation.
• Single-locus targeting: Most screens were performed at one genomic locus (FRMD7). Repair pathway preferences may vary with chromatin context or target site composition.
• Acute drug exposure: The effects of chronic or repeated drug treatment on DNA repair fidelity and cellular viability were not explored in this screen.
• Clinical translation: While all compounds are clinically approved, their safety in the context of genome editing or synthetic lethality applications in patients remains to be established.

Nonetheless, the core principle—that DNA repair pathway choice is pharmacologically tunable—holds broad potential for transfer to diverse settings, including ischemia and hypoxia research and precision gene therapy. The mechanistic insights regarding ESR2, AOX1, and repair protein cross-talk open new directions for combinatorial interventions and drug synergy studies.

Protocol Parameters

• Drug screening concentration: Compounds were generally tested at concentrations recommended for cellular assays, typically in the low micromolar range; adjust based on compound-specific cytotoxicity and solubility.
• Cas9 induction: Doxycycline-induced Cas9 expression timing and duration were optimized to achieve efficient editing without excessive genotoxicity; consider titration in alternative cell systems.
• Post-editing recovery: Allow sufficient recovery in drug-free medium before assessing cell viability and repair outcomes to minimize confounding acute drug toxicity.
• Sequencing analysis: Use high-fidelity amplicon sequencing and validated computational pipelines for accurate assignment of repair pathway outcomes.

Research Support Resources

Researchers seeking to modulate intracellular calcium signaling as part of DNA repair or synthetic lethality studies may consider Dantrolene, sodium salt (SKU B6329), a potent and calmodulin-dependent ryanodine receptor antagonist. This compound is well-characterized for its ability to inhibit RyR-mediated calcium release, a process increasingly recognized as influential in genome stability and cell fate determination. High-purity Dantrolene sodium salt supports reproducible experiments in calcium signaling modulation, disease modeling, and genome editing workflows. For additional protocol guidance and practical usage scenarios, see the reviews linked above.